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Abstract
Background: Gram-negative bacilli are primarily responsible for the most common pediatric infections. Frequently, Escherichia
fergusonii is identified as E. coli because of its close genetic proximity.
Objectives: We aimed at the isolation and identification of multi-resistant strains of E. fergusonii, affecting children under two
months of age.
Methods: Strains were isolated from infectious processes and were identified phenotypically and molecularly. The microdilution
method (MicroScan, autoSCAN-4) and the disk diffusion method (modified Kirby Bauer) were used to analyze antibiotic susceptibil-
ity.
Results: Strains isolated were multi-resistant. Molecular identification provided the correct taxonomic assignment. Escherichia
fergusonii strains were wrongly identified as E. coli with the phenotypic identification method. In addition, Pseudomonas aerug-
inosa and Klebsiella pneumoniae were identified. The best sensitivity results were obtained with Ceftazidime/avibactam and
ceftolozane/tazobactam.
Conclusions: We provided the first report of isolation and identification of multi-resistant E. fergusonii strains affecting children
under two months of age in a neonatal intensive care unit.
Keywords: Multi-resistant Bacteria, Antibiotics, Phenotypic Identification, Molecular Identification, Escherichia fergusonii
1. Background
Antibiotic resistance is expected to cause more deaths
than cancer by 2050, and it poses a severe threat to pub-
lic health (1, 2). Multidrug-resistant gram-negative bacilli
are the most frequent causes of sepsis and pneumonia in
newborns, causing death (3, 4). Escherichia coli is one of
the most common ones (5-7). There are eight recognized
species in the genus Escherichia (8). Escherichia coli is the
most studied one (9). Its closest relative is E. fergusonii, with
64% genetic similarity (10, 11). The proximity between the
two species gives rise to identification problems, depend-
ing on the method used.
With the use of phenotypic methods, E. fergusonii is
usually identified as E. coli (12, 13). Epidemiologically, bacte-
rial misclassification leads to underreporting pathogenic
microorganisms. Escherichia fergusonii emerges as a mi-
croorganism of concern because of its potential for multi-
drug resistance; however, it is underreported (13-15). There
are three reports of isolation in humans; two are clinical
cases (14, 15), and only one reports strains found in differ-
ent patients (13). Currently, the prevalence and incidence
of cases in which the bacterium causes disease are not
known precisely. It is also not known exactly how often it
becomes resistant to antimicrobial therapy.
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2. Objectives
We aimed to present the first report on the isolation
and molecular identification of multidrug-resistant E. fer-
gusonii strains (previously identified as E. coli) in infants
less than two months old in a neonatal intensive care unit.
3. Methods
3.1. Samples
A descriptive cross-sectional study was performed.
Samples of peripheral blood (n = 3), central blood (n = 1),
pleural fluid (n = 1), urine (n = 2), and injury discharge
(n = 2) were collected from patients under two months of
age, admitted to the Neonatal Intensive Care Unit of the
Maternal-Perinatal Hospital "Mónica Pretelini Sáenz" of the
Instituto de Salud del Estado de México (ISEM) in Toluca,
Mexico, from October 2019 to February 2020. Epidemiolog-
ical data were collected from each patient.
3.2. Culture
All samples were inoculated on the culture me-
dia, blood agar (Condalab 1108), Mannitol Salt (BD-BBL
254027), McConkey (BD-BBL 211662), and Biggy Agar (BD-
BBL 255002). The specific treatment of each sample was
as follows. Blood samples were placed in BacT/ALERT
culture medium (Biomerieux 10853) to optimize bacterial
recovery. They were subsequently inoculated by a cross
streak in the media already described. Pleural fluid and
urine samples were centrifuged at 2500 rpm for 10 min,
and the sediments obtained were inoculated by cross
streak. Injury discharge samples were collected using
the "Culture Swab Collection & Transport System" (BBL
HFT016) and inoculated by cross streak swabbing. All
inoculated culture media were incubated at 35 ± 2°C for
24 h. The macroscopic and microscopic morphological
characteristics of each strain were described.
3.3. Phenotypic Identification and Antimicrobial Susceptibility
Test with Microdilution Broth Method
Phenotypic identification and antibiotic susceptibil-
ity testing with the microdilution method were per-
formed with the MicroScan (autoSCAN-4, Beckman Coul-
ter®) according to the manufacturer’s instructions. Neg
Combo 67 (Beckman Coulter B1017-421) was used, which in-
cluded the following antibiotic families: Aminoglycosides,
Beta-lactams, Glycyclines, Polymyxins, Quinolones, Sulfon-
amides, and Tetracyclines.
3.4. Complementary Antibiotic Resistance Test by the Modified
Kirby-Bauer Disk Diffusion Method
The strains were subsequently tested for resistance
by disk diffusion using the modified Kirby-Bauer method,
with the addition of antibiotics not examined in the mi-
crodilution test. In addition, antibiotics from the Phenicol,
Phosphonate, and Nitrofuran families were added. A pure
18 - 24 h culture equivalent to 0.5 (1.5 × 108 cells) on the
McFarland scale was used. Discs with the selected antibi-
otics were placed in a Müller Hinton agar plate (BIO-RAD
63824) and incubated under aerobic conditions at 35± 2°C
for 18 - 24 h. For reading, the edge of the halo was visible to
the naked eye at the point of complete inhibition from the
back of the Petri dish against a black background illumi-
nated with reflected light (16). The diameter was measured
in millimeters and interpreted according to the CLSI M100
guide as sensitive (S), intermediate (I), or resistant (R) (16).
Multi-resistance was defined as simultaneous resistance to
three or more families of antibiotics from a minimum of 10
families (17). The collection strain E. coli ATCC® 25922 was
used for quality control (16).
3.5. Molecular Identification
Each strain was seeded in an enriched medium (BHI),
and incubated at 35± 2°C for 18 - 24 h under aerobic condi-
tions. Biomass was collected, centrifuged at 9,000 rpm for
five minutes, and the supernatant was decanted. The Wiz-
ard® Genomic DNA Purification Kit (Promega A1120) pro-
tocol was used to extract the genomic DNA, and the qual-
ity was checked by electrophoresis on a 1% agarose gel un-
der the following conditions: 120 V for 30 minutes with TAE
buffer 1X (TAE buffer Invitrogen 5M0311). The concentration
was quantified in the EPOCH spectrophotometer (BioTek)
at 260 and 280 nm.
Strains were identified by 16S rRNA gene sequencing
analysis. Universal primers 27F (5’-AGA GTT TGA TCM TGG
CTC AG-3’) and 1492R (5’-TAC GGY TAC CTT GTT ACG ACT T-3’)
were used. The Polymerase Chain Reaction (PCR) was car-
ried out in an Axygen thermal cycler (MaxyGen-II model),
using Taq DNA polymerase (Bioline 21105). The conditions
were as follows: an initial denaturation cycle of five min-
utes (94°C), denaturation of one minute (94°C), annealing
for 30 seconds (59°C), an extension for one minute (72°C).
Besides, 30 cycles were repeated, followed by a final exten-
sion cycle for 10 minutes (72°C).
The amplification products were observed in 1%
agarose gel electrophoresis under the same conditions
used previously, and the concentration was quantified
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with the EPOCH spectrophotometer. The PCR products
were purified using the Wizard® SV Gel and PCR Clean-Up
System kit (Promega A9282), and then sent to Macrogen®
Sequencing Service (Maryland, USA). Sequences were cor-
rected and assembled using BioEdit v7.2.5 software. They
were then compared with BLAST (Basic Local Alignment
Search Tool) software and the EzBioCloud public database.
4. Results
The characteristics of the patients and samples are
summarized in Table 1. Nine strains showed multi-drug re-
sistance in the microdilution method and disk diffusion
antibiograms. Eight of the nine strains were extended-
spectrum beta-lactamase (ESBL) producers (Table 2). The
two methods showed that all isolates (100%) were resistant
to aminoglycosides. Within the beta-lactams, nine strains
(100%) were resistant to penicillin and cephalosporins; 77%
were resistant to penicillin with inhibitor; strains Uro6
and Uro42 were the only ones resistant to carbapenems
(22%). Besides, 100% were resistant to quinolones and sul-
fonamides, and 88% were resistant to tetracyclines.
With the microdilution method, sensitivity to tigecy-
cline and colistin was detected in all strains (100%). Cef-
tazidime/avibactam and ceftolozane/tazobactam combi-
nations showed the best sensitivity results for all strains
tested with the disk diffusion method (Table 2). Bacte-
rial identification by phenotypic and molecular methods
showed differences in the taxonomic assignment of E.
fergusonii. Using molecular identification, strains Uro6,
Sec23, and Sec15, phenotypically categorized as E. coli, were
identified as E. fergusonii. In addition, five strains were
identified as Klebsiella pneumoniae and one as Pseudomonas
aeruginosa. These results were consistent with both identi-
fication methods. Complete identification data are shown
in Table 3.
5. Discussion
Neonatal sepsis is one of the leading causes of mortal-
ity in Mexico (3-7). The detection of multidrug-resistant
bacteria is essential for infection control, preventing their
spread and unfavorable morbidity and mortality implica-
tions. The appropriate use of antimicrobials represents
positive variables to reduce the burden of neonatal sepsis
(18). In this study, E. fergusonii was identified by phenotypic
methods as E. coli. However, by molecular techniques, a
more precise identification was achieved, coinciding with
previous publications that clarified the need to correctly
identify this species to complete a taxonomic assignment
and accurate epidemiological report (10-13).
Escherichia fergusonii was mainly isolated from injury
discharge, except for strain Uro6, which, together with
strain Uro42 (P. aeruginosa), was isolated from urine sam-
ples and had the highest antibiotic resistance. Both were
the only ones resistant to carbapenems. A previous study
revealed a similar pattern in septic wound isolates (13).
Our results provide new information about the presence
of multidrug-resistant E. fergusonii in urine samples.
In 1993, Funke et al. (19) isolated E. fergusonii from hu-
man clinical samples and concluded that the bacterium
had pathogenic potential; before this, it had not been as-
sociated with clinical infections. Current studies on this
subject are limited (19-22), and publications on its multi-
resistance associated with human pathologies are scarce
(13-15). We can affirm that this is the first report of the pres-
ence of the bacterium with multidrug-resistant patterns in
clinical samples from infants under two months of age ad-
mitted to a neonatal intensive care unit.
Strain Uro42, genetically identified as P. aeruginosa,
showed resistance to the most significant number of an-
tibiotics tested, including carbapenems. Several studies
have addressed the causes of this resistance (23-25). Our
results agree with that reported by Mohsen et al. (26),
who found 45% carbapenem-resistant Pseudomonas infec-
tion in infected neonates. Carbapenems are the last line of
defense against many drug-resistant bacterial infections.
Unfortunately, our study reaffirms that conditions due
to pathogens resistant to this drug are present in this
age group. Klebsiella pneumoniae was the most abundant
species, isolated from blood and pleural fluid. It is reported
as one of the predominant organisms in this type of pa-
tient (26-29). The strains were sensitive to carbapenems in
contrast to P. aeruginosa and E. fergusonii. Despite being
one of the most frequent bacteria in neonatal sepsis, our
results showed that its resistance patterns are lower than
those found in the other two species reported.
Although the microdilution technique (MicroScan)
is most widely used, the disk diffusion methodology
(modified Kirby-Bauer) showed important information,
such as enzymatic activity (beta-lactamases, metallo-beta-
lactamases), resistant mutants, antagonism, and syner-
gism between antibiotics; this provides a broader view
in the proper interpretation of the antibiogram. The mi-
crodilution method (MicroScan) made it possible to deter-
mine that the multidrug-resistant strains were sensitive
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Table 1. Characteristics of the Patients and Samples Included in the Study
Patients Sex Age Diagnosis Sample Type Sample Code
1 Male 60 days Sepsis Peripheral blood Hemo72
2 Male 5 days Sepsis Peripheral blood H1026
3 Female 21 days Sepsis Peripheral blood H1064
4 Male 30 days Sepsis Central blood H1206
5 Male 8 days Chylothorax Pleural fluid Sec2
6 Female 21 days Sepsis Urine Uro6
7 Male 38 days Transgestational urinary infection Urine Uro42
8 Male 14 days Injury with abscess Injury discharge Sec23
9 Male 14 days Neural tube deficiency Injury discharge Sec15
to tigecycline and colistin. However, these antibiotics are
not recommended for children under eight years of age,
and colistin is only recommended for children over two
years of age (30, 31). With the disk diffusion method, it
was possible to determine another sensitivity pattern. Cef-
tazidime/avibactam and ceftolozane/tazobactam may be
more useful in practice, specifically for the age group in-
cluded in this study.
Respecting the study’s limitations, we can mention
that it included a small number of cases in a single health
care hospital. It is difficult to generalize the results be-
cause the pathogens found in neonatal sepsis vary world-
wide. The type of sepsis was also not determined; this
would have provided important information as some stud-
ies showed that late sepsis and early-onset sepsis differ in
antibiotic susceptibility patterns, but some studies con-
tradict this claim (29). Among the strengths of our study,
we can mention that the latest generation antibiotics were
used. Besides, two methods were applied to determine re-
sistance patterns, which allowed us to calculate treatment
options according to the age of the patients. Phenotypic
and molecular methods were tested for correct bacterial
identification, which allowed us to determine the presence
of E. fergusonii, rarely reported and with an alarming de-
gree of antimicrobial resistance, in a sensitive age group.
5.1. Conclusions
Phenotypic testing did not allow reliable identification
to species level. The 16S rRNA gene sequencing was more
accurate for taxonomic assignment. Multidrug-resistant E.
fergusonii strains were identified for the first time in chil-
dren younger than two months. Ceftazidime/avibactam
and ceftolozane/tazobactam provided the best treatment
option for all strains, considering the age characteristics
of the patients. The knowledge generated may promote
targeted antibacterial therapy. This study may be of great
importance to measure the impact on the local epidemiol-
ogy of E. fergusonii and antimicrobial and multi-drug resis-
tance.
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Table 2. Patterns of Antibiotic Resistance and Sensitivity by Microdilution Method (MicroScan) and Disk Diffusion Method (modified Kirby-Bauer)
Antibiotic Family Method
Strains
Hemo72 H1026 H1064 H1206 Sec2 Uro6 Sec23 Sec15 Uro42
Aminoglycosides
Amikacine Aa S S S I S S S S R
Gentamycin A R S R R R S S S R
Netilmicin Bb R R R R R R R R R
Tobramycin A R S R R R R S S R
Beta-lactam
Penicillin
Ampicillin A, B R R R R R R R R ND
Piperazine A R R ND R ND ND ND ND R
Penicillin/inhibitor
Amoxicillin/clavulanic acid A ND ND I ND I R S S ND
Ampicillin/sulbactam A, B R R R R R R S S R
Piperacillin/tazobactam A, B R S I I S R S S R
Carbapenems
Doripenem B S S S S S R S S I
Ertapenem A S S S S S R S S ND
Imipenem A S S S S S R S S R
Meropenem A S S S S S R S S R
First-generation cephalosporin
Cefazolin B R R R R R R R R ND
Second-generation cephalosporin
Cefaclor B R R R R R R R R ND
Cefotetan A, B S S S S S R S S ND
Cefuroxime A R R R R R R R R ND
Third-generation cephalosporin
Cefoperazone B R R R R R R R R ND
Cefotaxime A, B R R Rc Rc Rc R Rc Rc ND
Cefpodoxime B R R R R R R R R ND
Ceftazidime A Rc Rc ND Rc Rc Rc Rc Rc R
Ceftibuten B R R R R R R S R ND
Ceftriaxone A Rc Rc Rc Rc Rc R Rc Rc ND
Third-generation cephalosporin/inhibitor
Ceftazidime/avibactam B S S S S S S S S S
Fourth-generation cephalosporins
Cefepime A, B R R R R R R R R R
Fifth-generation cephalosporins
Ceftaroline B R R R R R R R R ND
Fifth-generation cephalosporins/inhibitor
Ceftolozane/tazobactam B S S S S S S S S S
Phenicol
Chloramphenicol B R S R R I I I R ND
Phosphonates
Phoosphomycin B ND ND ND ND ND S ND ND R
Glycylcicline
Tigecyclin A S S S S S S S S ND
Nitrofurans
Nitrofurantoin B ND ND ND ND ND R ND ND ND
Polymyxins
Colistina A S S S S S S S S S
Quinolones
Second-generation quinolones
Ciprofloxacin A, B R R R R R R R R R
Third-generation quinolones
Levofloxacin A S S R S S R R R R
Sulfonamides
Trimethoprim/sulfamethoxazol A, B R R R R R R R R ND
Tetracyclines
Tetracycline A R S R R R R R R ND
Abbreviations: R, resistant; S, sensitive; I, intermediate; ND, Not determined.
a Microdilution method (MicroScan autoScan-Neg Combo 67, Beckman Coulter B1017-421)
b Disk diffusion, modifier Kirby-Bauer method (BIO-RAD, 71080280; 71080180; 12008071; 71080280; 71080280; 71080180. OXOID, CT0264B; CT1880B; CT0193B; CT1612B; CT1662B; CT1941B; CT0183B. BBL, 231659; 231691; 231592; 231652; 231655;
231695)
c R, positive to extended-spectrum beta-lactamases (ESBL) production
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Table 3. Phenotypic and Molecular Identification of Multi-resistant Strains
Strain code MicroScan
Molecular Identification
BLAST % Similarity Reference Strain EzBioCloud %
Similarity
Reference Strain Fragment Length
Hemo72 Klebsiella pneumoniae K. pneumoniae 100 DSM 30104 K. pneumoniae subsp
pneumoniae 99.1
DSM 30104 1500 bp
H1026 K. pneumoniae K. pneumoniae 100 DSM 30104 K. pneumoniae subsp
pneumoniae 100
DSM 30104 1438 bp
H1064 K. pneumoniae K. pneumoniae 100 DSM 30104 K. pneumoniae subsp
pneumoniae 100
DSM 30104 1456 bp
H1206 K. pneumoniae K. pneumoniae 100 DSM 30104 K. pneumoniae subsp
pneumoniae 99.1
DSM 30104 1520 bp
Sec2 K. pneumoniae K. pneumoniae 100 DSM 30104 K. pneumoniae subsp
pneumoniae 100
DSM 30104 1425 bp
Uro6 Escherichia coli E. fergusonii 100 ATCC 35469 E. fergusonii 99.92 ATCC 35469 1420 bp
Sec23 E. coli E. fergusonii 100 ATCC 35469 E. fergusonii 99.93 ATCC 35469 1464 bp
Sec15 E. coli E. fergusonii 100 ATCC 35469 E. fergusonii 99.93 ATCC 35469 1462 bp
Uro42 Pseudomonas
aeruginosa
P. aeruginosa 100 DSM 50071 P. aeruginosa 100 JCM 5962 1452 bp
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